营收增长40%：易瑞生物发布Q3财报

Financial Performance - The company's operating revenue for the current period is 76,346,216.83 CNY, representing a 40.34% increase compared to the same period last year [2] - The net profit attributable to shareholders is 15,683,546.58 CNY, showing a significant increase of 187.43% year-on-year [2] - The net profit after deducting non-recurring gains and losses is 5,785,957.24 CNY, which is a 225.48% increase compared to the same period last year [2] - The basic earnings per share (EPS) is 0.0391 CNY, reflecting a 187.50% increase year-on-year [2] Financial Indicators - Total assets at the end of the reporting period amount to 1,481,560,034.85 CNY, a 1.67% increase from the end of the previous year [2] - The equity attributable to shareholders is 908,090,377.01 CNY, which is a 4.50% increase compared to the previous year [2] - The weighted average return on equity is 1.78%, up from 1.14% in the same period last year [2] Cash Flow Analysis - The net cash flow from operating activities for the year-to-date is 7,828,976.36 CNY, which has decreased by 51.16% compared to the previous year [2] - The cash received from the disposal of fixed assets is 29,329,300.38 CNY, indicating a significant increase of 10,541.12% compared to the previous period [7] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 16,436 [9] - The largest shareholder, 易瑞(海南)创业投资有限公司, holds 32.68% of the shares, amounting to 132,369,971 shares [9] - The second-largest shareholder, 朱海, holds 14.85% of the shares, totaling 60,171,195 shares [9] Changes in Financial Position - Cash and cash equivalents increased by 53.31% to 449,803,934.39 CNY, primarily due to the redemption of financial products [7] - The company's inventory increased by 43.24% to 57,910,460.72 CNY, attributed to an increase in stock preparation [7] - The company's fixed assets rose by 57.10% to 570,435,095.39 CNY, mainly due to the completion of the 易瑞产业园 project [7]